Infectious Disease Research Institute

Vaccine Center of Innovation launches

Thursday, October 22, 2015

In an effort to accelerate timelines and decrease development costs of life-saving vaccines, the Infectious Disease Research Institute (IDRI) and Sanofi Pasteur have established the Global Health Vaccine Center of Innovation (GHVCI), to be based at IDRI in Seattle. The project is funded in part by a grant from the Bill & Melinda Gates Foundation. The GHVCI represents an alliance among the three organizations, focused on accelerating the development of vaccines and associated technologies to fight a wide range of global infectious diseases, and ensuring that those critical vaccines are accessible globally, especially to people in need within developing countries.

[Read More]

IDRI supports first phase I human hookworm vaccine trial

Wednesday, February 1, 2012

The Infectious Disease Research Institute (IDRI) has joined Sabin Vaccine Institute‘s venture to develop a human hookworm vaccine—which affects 600 million people worldwide—by contributing a proprietary adjuvant as a component. The phase I trial, which began last week in Brazil, aims to reduce the global burden of human hookworm by providing effective long-term protection for those who are most at risk.

[Read More]

IDRI joins ADITEC to accelerate human vaccine development

Tuesday, October 18, 2011

The Infectious Disease Research Institute (IDRI) has joined the Advanced Immunization Technologies (ADITEC) program, a collaborative initiative dedicated to accelerating the development of the next generation of human vaccines. Launched on October 1st, ADITEC will operate with 30 million euros in funding over the course of 5 years contributed by the European Union, with an additional 11 million euros in funding from collaborating organizations.

[Read More]